Treatment of refractory and recurrent Clostridium difficile infection

被引：68

作者：

Surawicz, Christina M. ^{[1
]}

Alexander, Jacob ^{[1
]}

机构：

[1] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98104 USA

来源：

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2011年 / 8卷 / 06期

关键词：

IN-VITRO ACTIVITY; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; EMERGENCY COLECTOMY; ANTIBODY-RESPONSE; CONTROLLED-TRIAL; ORAL VANCOMYCIN; FUSIDIC ACID; CASE SERIES; TOXIN-A;

D O I：

10.1038/nrgastro.2011.59

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The incidence of Clostridium difficile infection (CDI) has increased since 2000, with greater numbers of severe cases reported, in part due to the emergence of a hypervirulent strain. Initial therapy with metronidazole is still recommended for mild to moderate CDI, but vancomycin is recommended for first-line therapy of severe CDI. Colectomy could be life-saving for some patients with severe disease that does not respond to maximal medical therapy. Recurrent CDI is a challenge to treat; no single effective therapy currently exists. Treatments include antibiotics, adjunct probiotics, fecal microbiota transplant and immune approaches. This Review discusses the various therapeutic approaches used for the treatment of refractory and recurrent CDI.

引用

页码：330 / 339

页数：10

共 105 条

[1] Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].

Aas, J ;

Gessert, CE ;

Bakken, JS .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585

[2] Intravenous Immunoglobulin for the Treatment of Clostridium difficile Infection: A Review [J].

Abougergi, Marwan S. ;

Kwon, John H. .

DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (01) :19-26

[3]

Abougergi Marwan S, 2010, J Hosp Med, V5, pE1, DOI 10.1002/jhm.542

[4] Outcomes of emergency colectomy for fulminant Clostridium difficile colitis [J].

Al-Abed, Yahya A. ;

Gray, Emma A. ;

Rothnie, Neil D. .

SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2010, 8 (06) :330-333

[5] Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin [J].

Al-Nassir, Wafa N. ;

Sethi, Ajay K. ;

Nerandzic, Michelle M. ;

Bobulsky, Greg S. ;

Jump, Robin L. P. ;

Donskey, Curtis J. .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) :56-62

[6]

Ananthakrishnan AN, 2010, EXPERT REV GASTROENT, V4, P589, DOI [10.1586/egh.10.55, 10.1586/EGH.10.55]

[7] Clostridium Difficile and Inflammatory Bowel Disease: More Questions than Answers? COMMENT [J].

Ananthakrishnan, Ashwin N. ;

Binion, David G. .

INFLAMMATORY BOWEL DISEASES, 2010, 16 (08) :1445-1446

[8] Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis:: Case series and review of the literature [J].

Apisarnthanarak, A ;

Razavi, B ;

Mundy, LM .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (06) :690-696

[9] Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001 [J].

Archibald, LK ;

Banerjee, SN ;

Jarvis, WR .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) :1585-1589

[10] Treatment of Clostridium difficile-associated disease:: old therapies and new strategies [J].

Aslam, S ;

Hamill, R ;

Musher, DM .

LANCET INFECTIOUS DISEASES, 2005, 5 (09) :549-557

← 1 2 3 4 5 6 7 8 9 10 →